J&J’s Top 10 List: Updates From Pharma Business Review
Executive Summary
J&J presented a far-reaching overview of its pharmaceutical portfolio and pipeline at an analyst day May 20, including plans to break into immuno-oncology, a strategy to develop a pan-genotypic HCV regimen and several filing timelines for new drugs.
You may also be interested in...
Bapineuzumab Failure Raises More Doubts About Beta Amyloid Approach In Alzheimer’s
As many observers expected, top-line results from a Phase III study show bapineuzumab doesn’t work in carriers of the ApoE4 gene, who are at highest risk for Alzheimer’s disease. An interim analysis of another Phase III study in carriers will now be “expedited,” and other studies of non-carriers will keep going, Pfizer says.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.